Comparison of calculated and observed residual risks of transfusion-transmitted hepatitis C virus infection in multiply transfused patients. French Study Group on Thalassaemia
De Montalembert, M.; Lefrère, J.J.; Micheau, M.; Girot, R.
Transfusion 34(8): 737-738
1994
ISSN/ISBN: 0041-1132
PMID: 8073492
DOI: 10.1046/j.1537-2995.1994.34894353472.x
Accession: 045590484
PDF emailed within 0-6 h: $19.90
Related References
De Montalembert, M.; Costagliola, D.G.; Lefrère, J.J.; Cornu, G.; Lombardo, T.; Cosentino, S.; Perrimond, H.; Girot, R. 1992: Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. the French Study Group on Thalassaemia Transfusion 32(6): 509-512Poovorawan, Y.; Theamboonlers, A.; Chongsrisawat, V.; Seksarn, P.; Jarvis, L.; Simmonds, P. 1998: High prevalence of hepatitis G virus infection in multiply transfused children with thalassaemia Journal of Gastroenterology and Hepatology 13(3): 253-256
Lau, Y.L.; Chow, C.B.; Lee, A.C.; Ng, K.W.; Lim, W.L.; Chan, C.F.; Lam, S.Y.; Li, C.K. 1993: Hepatitis C virus antibody in multiply transfused Chinese with thalassaemia major Bone Marrow Transplantation 12(Suppl 1): 26-28
Coimbra, Joao Carlos; Pinto, Iraja Damiani; Wurdig, Norma Luiza; Do Carmo, Dermeval Aparecido 1990: Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major Journal of Clinical Pathology 43(8): 638-640
Lelie, N.; Busch, M.; Kleinman, S. 2021: Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components: a review of observed versus modeled infectivity from donors with window period and occult HBV infections Transfusion 61(11): 3190-3201
Kengne, M.; Medja, Y.F.O.; Tedom; Nwobegahay, J.M. 2021: Residual risk for transfusion-transmitted hepatitis B virus infection due to occult hepatitis B virus infection in donors living in Yaoundé, Cameroon Pan African Medical Journal 39: 175
Ballester, J.é M.; Rivero, R.é A.; Villaescusa, R.; Merlín, J.C.; Arce, A.A.; Castillo, D.; Lam, R.M.; Ballester, A.; Almaguer, M.; Melians, S.M.; Aparicio, J.é L. 2005: Hepatitis C virus antibodies and other markers of blood-transfusion-transmitted infection in multi-transfused Cuban patients Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 34(Suppl 2): S39-S46
Kim, M.J.; Park, Q.; Min, H.K.; Kim, H.O. 2012: Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 Bmc Infectious Diseases 12: 160
Rebulla, P.; Mozzi, F.; Contino, G.; Locatelli, E.; Sirchia, G. 1992: Antibody to hepatitis C virus in 1,305 Italian multiply transfused thalassaemics: a comparison of first and second generation tests. Cooleycare Group Transfusion Medicine 2(1): 69-70
Taira, R.; Satake, M.; Momose, S.'y.; Hino, S.; Suzuki, Y.; Murokawa, H.; Uchida, S.; Tadokoro, K. 2013: Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan Transfusion 53(7): 1393-1404
Wang, J.; Liu, J.; Yao, F.; Wen, G.; Li, J.; Huang, Y.; Lü, Y.; Wen, X.; Wright, D.; Yu, Q.; Guo, N.; Ness, P.; Shan, H.; Yang, T.; Dong, X.; Bi, X.; Li, J.; Ma, H.; Huang, M.; Schulman, J.; King, M.; Kavounis, K.; Song, G.; Gu, J.; Glynn, S.A. 2013: Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors Transfusion 53(6): 1240-1249
Seed, C.R.; Kiely, P. 2013: A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening Vox Sanguinis 105(4): 290-298
Velati, C.; Romanò, L.; Pati, I.; Marano, G.; Piccinini, V.; Catalano, L.; Pupella, S.; Vaglio, S.; Veropalumbo, E.; Masiello, F.; Pisani, G.; Grazzini, G.; Zanetti, A.; Liumbruno, G.M. 2019: Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018 Blood Transfusion 17(6): 409-417
Donohue, S.M.; Wonke, B.; Dusheiko, G.; Hoffbrand, A.V. 1991: Alpha interferon therapy of hepatitis c in multiply transfused thalassaemia patients Journal of Interferon Research 11(Suppl 1): S124
Beeby, P.J.; Spencer, J.D.; Cossart, Y.E. 2001: Risk of hepatitis C virus infection in multiply transfused premature neonates Journal of Paediatrics and Child Health 37(3): 244-246
Beltrán, M.; Navas, M.ía.C.; Arbeláez, M.ía.P.; Donado, J.; Jaramillo, S.; De la Hoz, F.; Estrada, C.; Cortés, L.ía.d.P.; de Maldonado, A.; Rey, G. 2009: Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia Biomedica: Revista del Instituto Nacional de Salud 29(2): 232-243
Gonzalez, M.; Règine, V.; Piccinini, V.; Vulcano, F.; Giampaolo, A.; Hassan, H.Jane. 2005: Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy Transfusion 45(10): 1670-1675
Telfer, P.T.; Whitby, K.; Garson, J.A.; Hoffbrand, A.V.; Wonke, B. 1995: Alpha interferon alone and in combination with ribavirin for hepatitis C virus infection in multiply transfused thalassaemic patients Blood 86(10 Suppl 1): 484A
Feitelson, M.A.; Taddei, M.G.; Ballas, S.K. 1996: Evidence for underlying hepatitis B virus infection among multiply transfused patients with sickle cell anemia Blood 88(10 Suppl 1 Part 1-2): 527A
Telfer, P.T.; Whitby, K.; Grant, P.; Garson, J.A.; Hoffbrand, A.V.; Wonke, B. 1996: Combination therapy with interferon alpha and ribavirin for hepatitis C virus infection in multiply transfused thalassaemic patients Blood 88(10 Suppl 1 Part 1-2): 527A